Patrick Mollon - Concepedia

Author

Patrick Mollon

Pfizer (United States)

Also Known As

P Mollon, P. Mollon, Patrick Mollon

Publications

927

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)New England Research Institutes Cornell University Pfizer (United Kingdom)Northwestern University

About

Patrick Mollon is an author at Pfizer (United States) specializing in medicine, urology, and chronic kidney disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	226
2	Public Health	2	2	100
3	Health Sciences	1	1	20
4	Diabetes	1	1	73
5	Epidemiology	1	1	86

Patrick Mollon

Publications

784

Citations

H-Index

Page 1

	Year	Citations
Association of Lower Urinary Tract Symptoms and the Metabolic Syndrome: Results From the Boston Area Community Health Survey Varant Kupelian, Kevin T. McVary, Steven A. Kaplan, The Journal of Urology	2009	197
Association of Urological Symptoms and Chronic Illness in Men and Women: Contributions of Symptom Severity and Duration—Results From the BACH Survey Varant Kupelian, Raymond C. Rosen, Carol L. Link, The Journal of Urology	2008	96
Association of C-reactive Protein and Lower Urinary Tract Symptoms in Men and Women: Results From Boston Area Community Health Survey Varant Kupelian, Kevin T. McVary, Michael J. Barry, Urology Urological ResearchUrologyMedicineClinical EpidemiologyGeriatric Urology	2009	86
Association of Lower Urinary Tract Symptoms and the Metabolic Syndrome: Results From the Boston Area Community Health Survey Varant Kupelian, Kevin T. McVary, Steven A. Kaplan, The Journal of Urology Metabolic DisorderErectile DysfunctionRenal PathologyUrological SymptomsObesity	2012	73
Lower urinary tract symptoms and sexual health: the role of gender, lifestyle and medical comorbidities Raymond C. Rosen, Carol L. Link, Michael P. O’Leary, British Journal of Urology	2009	60
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma Robin Kate Kelley, Patrick Mollon, Jean‐Frédéric Blanc, Advances in Therapy	2020	56
Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database Steven R. Feldman, Haijun Tian, I. Gilloteau, BMC Health Services Research	2017	53
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept Bruce Strober, Alice B. Gottlieb, Bintu Sherif, Journal of the American Academy of Dermatology InflammationCytokinePhase IiiImmunologyClinical Trials	2017	33
Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms Steven A. Kaplan, Claus G. Roehrborn, Christopher R. Chapple, British Journal of Urology	2009	29
Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial. Ghassan K. Abou‐Alfa, Patrick Mollon, Tim Meyer, Journal of Clinical Oncology Quality Of LifeLife AssessmentPharmacotherapyLogistic AnalysisSocial Health	2019	20

Page 1